CSL Plasma donor profile and survey results CSL is grateful to its plasma donors, who have shared with us that they donate plasma for a number of reasons. Some donors have been personally impacted by the generosity of plasma donations, through a loved one with a rare condition or who has needed plasma-derived products in an emergency. Other donors use the payment to supplement their income, to make ends meet, or to reach a goal. Each person has their own reasons for donating plasma and their donation makes a major difference for those who rely on plasma-derived therapies. CSL Plasma is continuing to learn more about donors, who they are, what they do and why they donate plasma. CSL’s goal is to provide a positive donor experience for everyone who enters a CSL plasma centre. Based on self-reported survey data** administered through the CSL Plasma mobile app for CSL’s US donors, (1 July 2024 to 30 June 2025), CSL Plasma donors provided details on their occupational status:* • 52% described themselves as working full time. • 20% described themselves as unemployed, inclusive of full time parents, donors who are not looking for work or the unemployed. • 15% described themselves as part time. • 2% described themselves as students. • 11% described themselves as other (e.g. military, retired). Of those plasma donors surveyed, 93% are willing to donate again, and 90% of plasma donors are willing to refer a friend or family to donate plasma at their CSL Plasma donor centre.* 90% of plasma donors are willing to refer a friend or family to donate plasma at their CSL Plasma centre* 93% of plasma donors willing to donate again* Products quality and safety The development, manufacture and supply of high-quality and safe products is critical to CSL’s ability to continue to protect public health, save lives and improve the health and wellbeing of patients with rare and serious diseases. CSL’s independent quality function strives to maintain the highest standards using global quality standards and systems. These are reflected in global policies and global and local procedures, as well as global electronic systems to support management of the quality processes. In the reporting period, CSL’s quality systems, plasma collection and manufacturing operations were subject to a total of 403 regulatory agency inspections* around the world. Of these, 27 good manufacturing practice (GMP) regulatory agency inspections* took place at CSL manufacturing facilities and distribution centres, and 376 regulatory inspections* at plasma collection centres. These independent inspections resulted in no critical findings* that prevented release of commercial product and no suspensions or terminations of licenses to market any products in markets in which CSL is active. These results confirm that the quality systems established globally by CSL are effective and in line with regulatory agency expectations. In the reporting period there were two product recalls*. In August 2024, CSL Seqirus initiated a Class II recall* for an in-licensed product, for which CSL Seqirus Pty Ltd is the Marketing Authorisation Holder in Australia. The recall was triggered by a complaint regarding a 100 mg tablet being found in a 50 mg blister pack. The affected product was not physically removed from the market and notifications were issued to distributors and customers. A thorough review and investigation was performed by the in-license partner, who manufactures and packages this product. The investigation determined that this was an isolated incident. In October 2024, CSL Behring initiated a Class II recall* for Hepatitis B Immunoglobulin due to incorrect labelling on the vial and carton. No product was removed from the market. Corrective and preventive actions were implemented to prevent recurrence. This year, there were nine counterfeit products reported to and confirmed by CSL Behring. CSL Behring is implementing packaging security solutions that will make it more difficult for counterfeiters to replicate CSL’s products and will make identification of counterfeit products easier. In addition, CSL Behring is partnering with global health authorities to alert customers, healthcare representatives and patients on how to identify, handle and report suspected counterfeit products. 403 regulatory inspections resulted in no critical findings that prevented release of commercial product, no suspensions or terminations of licenses to market any products in markets in which CSL is active* * Limited assurance by Deloitte. ** Survey data is based on 1.8 million survey responses. The percentages for willing to donate and refer a friend comprises the total number of respondents who selected the top two (4 and 5) of five numbers on the Likert scale. 33 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3